Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
Saved in:
Main Authors: | Tuon,Felipe Francisco, Santos,Carolina Rocio, Cieslinski,Juliette, Souza,Regina Maia de, Imamura,Rui, Amato,Valdir Sabbaga |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto de Medicina Tropical de São Paulo
2018
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652018005000705 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Amphotericin B is usually underdosed in the treatment of experimental cutaneous leishmaniasis
by: Sifontes-Rodríguez,Sergio, et al.
Published: (2022) -
Disseminated tegumentary leishmaniasis refractory to liposomal amphotericin B treatment
by: Borges,Ana Flávia, et al.
Published: (2021) -
Comparison of Amphotericin B Lipid Complex (Abelcet) and Liposomal Amphotericin B (Ambisome) on Rat Kidney: a Morphological Evaluation
by: Mutluay,S. Deniz, et al.
Published: (2012) -
New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
by: Chávez-Fumagalli,Miguel Angel, et al.
Published: (2015) -
Azithromycin in the treatment of mucosal leishmaniasis
by: Silva-Vergara,Mario León, et al.
Published: (2004)